Adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia: meta-analysis of randomized controlled trials.

<h4>Objective</h4>To compare the safety and efficacy of adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia.<h4>Methods</h4><h4>Population</h4>adult patients presenting with antipsychotic-induced hyperprolactinemia diagnosed by prol...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Xianbin Li, Yilang Tang, Chuanyue Wang
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2013
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/4cfa137a5aca45f79cbcbad31f0db9ab
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4cfa137a5aca45f79cbcbad31f0db9ab
record_format	dspace
spelling	oai:doaj.org-article:4cfa137a5aca45f79cbcbad31f0db9ab2021-11-18T09:01:42ZAdjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia: meta-analysis of randomized controlled trials.1932-620310.1371/journal.pone.0070179https://doaj.org/article/4cfa137a5aca45f79cbcbad31f0db9ab2013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23936389/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Objective</h4>To compare the safety and efficacy of adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia.<h4>Methods</h4><h4>Population</h4>adult patients presenting with antipsychotic-induced hyperprolactinemia diagnosed by prolactin level with or without prolactin-related symptoms.<h4>Interventions</h4>adjunctive aripiprazole vs. adjunctive placebo.<h4>Outcome measures</h4>adverse events and efficacy of treatment.<h4>Studies</h4>randomized controlled trials.<h4>Results</h4>Five randomized controlled trials with a total of 639 patients (326 adjunctive aripiprazole, 313 adjunctive placebo) met the inclusion criteria. Adjunctive aripiprazole was associated with a 79.11% (125/158) prolactin level normalization rate. Meta-analysis of insomnia, headache, sedation, psychiatric disorder, extrapyramidal symptom, dry mouth, and fatigue showed no significant differences in the adjunctive aripiprazole treatment group compared with the placebo group (risk difference (Mantel-Haenszel, random or fixed) -0.05 to 0.04 (95% confidence interval -0.13 to 0.16); I(2) =0% to 68%, P=0.20 to 0.70). However, sedation, insomnia, and headache were more frequent when the adjunctive aripiprazole dose was higher than 15 mg/day. Meta-analysis of the prolactin level normalization indicated adjunctive aripiprazole was superior to placebo (risk difference (Mantel-Haenszel, random) 0.76 (95% confidence interval 0.67 to 0.85); I(2) =43%, P<0.00001). The subgroup analysis confirmed that the subjects who received adjunctive aripiprazole 5 mg/day showed a degree of prolactin normalization similar to that of all participants. No significant differences between groups in discontinuation and improvements of psychiatric symptoms.<h4>Conclusion</h4>Adjunctive aripiprazole is both safe and effective as a reasonable choice treatment for patients with antipsychotic-induced hyperprolactinemia. The appropriate dose of adjunctive aripiprazole may be 5 mg/day.Xianbin LiYilang TangChuanyue WangPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 8, p e70179 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Xianbin Li Yilang Tang Chuanyue Wang Adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia: meta-analysis of randomized controlled trials.
description	<h4>Objective</h4>To compare the safety and efficacy of adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia.<h4>Methods</h4><h4>Population</h4>adult patients presenting with antipsychotic-induced hyperprolactinemia diagnosed by prolactin level with or without prolactin-related symptoms.<h4>Interventions</h4>adjunctive aripiprazole vs. adjunctive placebo.<h4>Outcome measures</h4>adverse events and efficacy of treatment.<h4>Studies</h4>randomized controlled trials.<h4>Results</h4>Five randomized controlled trials with a total of 639 patients (326 adjunctive aripiprazole, 313 adjunctive placebo) met the inclusion criteria. Adjunctive aripiprazole was associated with a 79.11% (125/158) prolactin level normalization rate. Meta-analysis of insomnia, headache, sedation, psychiatric disorder, extrapyramidal symptom, dry mouth, and fatigue showed no significant differences in the adjunctive aripiprazole treatment group compared with the placebo group (risk difference (Mantel-Haenszel, random or fixed) -0.05 to 0.04 (95% confidence interval -0.13 to 0.16); I(2) =0% to 68%, P=0.20 to 0.70). However, sedation, insomnia, and headache were more frequent when the adjunctive aripiprazole dose was higher than 15 mg/day. Meta-analysis of the prolactin level normalization indicated adjunctive aripiprazole was superior to placebo (risk difference (Mantel-Haenszel, random) 0.76 (95% confidence interval 0.67 to 0.85); I(2) =43%, P<0.00001). The subgroup analysis confirmed that the subjects who received adjunctive aripiprazole 5 mg/day showed a degree of prolactin normalization similar to that of all participants. No significant differences between groups in discontinuation and improvements of psychiatric symptoms.<h4>Conclusion</h4>Adjunctive aripiprazole is both safe and effective as a reasonable choice treatment for patients with antipsychotic-induced hyperprolactinemia. The appropriate dose of adjunctive aripiprazole may be 5 mg/day.
format	article
author	Xianbin Li Yilang Tang Chuanyue Wang
author_facet	Xianbin Li Yilang Tang Chuanyue Wang
author_sort	Xianbin Li
title	Adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia: meta-analysis of randomized controlled trials.
title_short	Adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia: meta-analysis of randomized controlled trials.
title_full	Adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia: meta-analysis of randomized controlled trials.
title_fullStr	Adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia: meta-analysis of randomized controlled trials.
title_full_unstemmed	Adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia: meta-analysis of randomized controlled trials.
title_sort	adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia: meta-analysis of randomized controlled trials.
publisher	Public Library of Science (PLoS)
publishDate	2013
url	https://doaj.org/article/4cfa137a5aca45f79cbcbad31f0db9ab
work_keys_str_mv	AT xianbinli adjunctivearipiprazoleversusplaceboforantipsychoticinducedhyperprolactinemiametaanalysisofrandomizedcontrolledtrials AT yilangtang adjunctivearipiprazoleversusplaceboforantipsychoticinducedhyperprolactinemiametaanalysisofrandomizedcontrolledtrials AT chuanyuewang adjunctivearipiprazoleversusplaceboforantipsychoticinducedhyperprolactinemiametaanalysisofrandomizedcontrolledtrials
_version_	1718421019293646848

Adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia: meta-analysis of randomized controlled trials.

Ejemplares similares